All In Biotech

Drug Trial Radar · NCT00017784

Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment

Last checked: Nov 20, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

500

Actual

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to make valganciclovir available, before it is approved for marketing, to HIV-infected patients who have cytomegalovirus (CMV) retinitis (eye infection) and cannot take drugs by injection. This study also will look at the safety of using valganciclovir as starting and/or ongoing therapy. CMV can cause serious AIDS-related infections in patients with HIV. Drugs that are effective against CMV eye infections can be given only by injection; this calls for a thin tube to be placed into a vein in the chest so that the patient is not put through getting too many needle sticks. An experimental drug, valganciclovir, is similar to 1 of these approved drugs, ganciclovir, but is more convenient and easier to use since it can be taken by mouth. Once in the body, valganciclovir changes to ganciclovir. Studies have shown that valganciclovir tablets can result in the same level of ganciclovir in the blood as ganciclovir injection.

Conditions

  • Cytomegalovirus Retinitis
  • HIV Infections

Interventions

  • ValganciclovirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Retina - Vitreous Associates Med Group

    Beverly Hills, California

  • Wilbert Jordan

    Paramount, California

  • Quest Clinical Research

    San Francisco, California

  • Santa Clara Valley Med Ctr

    San Jose, California

  • IDC Research Initiative

    Altamonte Springs, Florida

  • Ingenix Kern McNeill Decatur

    Atlanta, Georgia

  • Nashville Health Management Foundation / Vanderbilt Univ

    Nashville, Tennessee

  • North Texas Infectious Disease Consultants

    Dallas, Texas

  • Fundacion Gastroenterologia de Diego

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.